Lyell Immunopharma (LYEL) Q2 2026 earnings summary

Executive summary

• Advanced pivotal trials for dual-targeting CAR T-cell therapy (ronde-cel) in large B-cell lymphoma (LBCL), with additional data expected in 2H 2026 and pivotal data in mid-2027.

• Acquired global rights (ex-China) to LYL273, a GCC-targeted CAR T-cell for metastatic colorectal cancer (mCRC), with promising Phase 1 results and ongoing trial expansion.

• Manufacturing successfully transitioned to the LyFE facility, supporting clinical and potential commercial supply.

• Reported second quarter 2026 financial results and business highlights, focusing on late-stage clinical progress in CAR T-cell therapies.

• Key clinical programs include ronde-cel for LBCL and LYL273 for mCRC.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $228.0 million as of June 30, 2026, expected to fund operations into Q3 2027.

• Net loss was $44.8 million for Q2 2026 and $68.9 million for the first half of 2026, both improved from prior year periods.

• Research and development expenses were $39.5 million for Q2 2026, up $4.7 million year-over-year due to increased clinical trial activity.

• General and administrative expenses decreased to $9.6 million for Q2 2026, reflecting lower personnel and professional costs.

• $50 million raised in March 2026 via equity issuance under a Securities Purchase Agreement.

Outlook and guidance

• Existing cash resources expected to fund operations into Q3 2027.

• Additional capital will be required for late-stage development and commercialization.

• Key upcoming milestones: pivotal data for ronde-cel in mid-2027, BLA submission in 2H 2027, and expanded LYL273 trial data in 2H 2026.

• Progress update for the PINACLE-H2H Phase 3 trial in 2L LBCL expected in H2 2026.

• Additional Phase 1 data and an End-of-Phase 1 FDA meeting for LYL273 in mCRC expected in H2 2026.